Form 4: Director Sandler Acquires ALXO Stock Options

ALX Oncology Holdings Inc. Director Alan B. Sandler was granted 10,100 stock options with an exercise price of $1.32, vesting monthly starting February 20, 2026.

Summary

• Director Alan B. Sandler of ALX Oncology Holdings Inc. (ALXO) was granted 10,100 stock options.
• The options have an exercise price of $1.32 per share.
• The options will vest in 12 equal monthly installments, commencing on February 20, 2026.
• The expiration date for these options is January 19, 2036.
• Following this transaction, Sandler directly beneficially owns 10,100 derivative securities.

Sentiment

Score: 7

Explanation: The grant of stock options to a director is a positive signal of continued alignment of interests and confidence in future growth, though it's a routine compensation event rather than a major strategic announcement.

Positives

• Director Alan B. Sandler was granted 10,100 stock options, indicating continued alignment of management interests with shareholder value.
• The grant of options at an exercise price of $1.32 suggests a belief in future stock price appreciation above this level.

Negatives

• NA

Risks

• The value of the stock options is dependent on the future market price of ALX Oncology Holdings Inc. common stock exceeding the exercise price of $1.32.
• There is a risk that the stock price may not appreciate sufficiently, or may decline, rendering the options worthless or less valuable.

Future Outlook

The grant of stock options with a long expiration date (January 19, 2036) and a vesting schedule extending over 12 months starting February 20, 2026, suggests a long-term incentive for the director, aligning their interests with the company's future performance and growth.

Industry Context

This is a routine insider transaction (stock option grant) for a director in the biotechnology/oncology sector. Such grants are common practice to incentivize and retain key personnel, aligning their financial interests with the long-term success of the company, which is particularly important in R&D-intensive industries like oncology.

Comparison to Industry Standards

• The grant of stock options to directors is a standard compensation practice across the biotechnology and pharmaceutical industries, similar to companies like Amgen, Gilead Sciences, or Bristol Myers Squibb, which frequently use equity-based incentives to align executive and director interests with shareholder value.
• The vesting schedule of 12 equal monthly installments is a common approach to ensure continued commitment and retention over a defined period, comparable to typical equity grants seen at peer companies.
• The exercise price of $1.32, likely the closing price on the grant date, is standard for at-the-money option grants.

Stakeholder Impact

• Shareholders: The grant aligns the director's long-term interests with shareholder value creation, as the options gain value only if the stock price increases above the exercise price.
• Employees: No direct impact on general employees is indicated by this filing.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders is indicated.

Next Steps

• The stock options will begin vesting in 12 equal monthly installments starting February 20, 2026.
• Director Alan B. Sandler will be able to exercise vested options at the $1.32 strike price until the expiration date of January 19, 2036.

Key Dates

Recommendation

This Form 4 reports a routine grant of stock options to a director, which is a standard compensation practice aimed at aligning management incentives with long-term shareholder value. While it signals continued commitment from the director, it does not provide new fundamental information about the company's operational or financial performance that would warrant a change in investment thesis. Therefore, a 'hold' recommendation is appropriate, maintaining current positions while awaiting more substantive operational or financial updates.

Keywords

ALX Oncology Holdings Inc., ALXO, Stock Options, Insider Trading, Form 4, Director Compensation, Equity Grant, Alan B. Sandler